Plasmodium falciparum Multidrug Resistance Proteins (pfMRPs)
The capacity of the lethal Plasmodium falciparum parasite to develop resistance against anti-malarial drugs represents a central challenge in the global control and elimination of malaria. Historically, the action of drug transporters is known to play a pivotal role in the capacity of the parasite t...
Saved in:
| Published in: | Frontiers in pharmacology Vol. 12; p. 759422 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Frontiers Media S.A
01-11-2021
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The capacity of the lethal
Plasmodium falciparum
parasite to develop resistance against anti-malarial drugs represents a central challenge in the global control and elimination of malaria. Historically, the action of drug transporters is known to play a pivotal role in the capacity of the parasite to evade drug action. MRPs (Multidrug Resistance Protein) are known in many phylogenetically diverse groups to be related to drug resistance by being able to handle a large range of substrates, including important endogenous substances as glutathione and its conjugates.
P. falciparum
MRPs are associated with in vivo and in vitro altered drug response, and might be important factors for the development of multi-drug resistance phenotypes, a latent possibility in the present, and future, combination therapy environment. Information on
P. falciparum
MRPs is scattered in the literature, with no specialized review available. We herein address this issue by reviewing the present state of knowledge. |
|---|---|
| Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Didier Leroy, Medicines for Malaria Venture, Switzerland Edited by: Rafael V. C. Guido, University of São Paulo, Brazil Reviewed by: Anna Caroline Aguiar, Federal University of São Paulo, Brazil This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology |
| ISSN: | 1663-9812 1663-9812 |
| DOI: | 10.3389/fphar.2021.759422 |